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Mild hyperhomocysteinemia promotes renal hemodynamic
dysfunction without histopathologic changes in adult rats.
Background. Hyperhomocysteinemia is able to promote
glomerular damage and generate tubulointerstitial lesions.
These findings were reported in rats with unilateral nephrec-
tomy or in weanling rats with normal function, two experimen-
tal models that are exposed to other concomitant vascular risk
factors. The aim of this work is to study whether mild hyperho-
mocisteinemia per se can induce renal histopathologic changes
in adults rats with normal renal function at either 10 or 44 weeks
of hyperhomocysteinemia.
Methods. Two months old male Wistar rats (N = 52)
were randomly allocated to either a normal control (N
= 26) or hyperhomocysteinemic (N = 26) group. Con-
trol and hyperhomocysteinemic groups had free access
to either tap water or homocysteine thiolactone 50 mg/
kg/day, during 10 or 44 weeks. Plasma homocysteine levels
were determined by a high-performance liquid chromatogra-
phy (HPLC) method. Glomerular filtration rate (GFR) and re-
nal plasma flow (RPF) were calculated from inulin and sodium
para-aminohippurate (PAH) clearance determinations. Struc-
tural renal changes were investigated in kidneys fixed by perfu-
sion. Histopathologic and morphometric analysis were carried
out by standard methods.
Results. Plasma total homocysteine levels were 53%
(10 weeks) and 56% (44 weeks) higher in hyperhomocysteine-
mic group compared to the control group. GFR and RPF were
significantly lower in hyperhomocysteinemic than in control
group. The histopathologic and morphometric studies did not
show any differences between the control and hyperhomocys-
teinemic rats at 10 or 44 weeks.
Conclusion. The present results show that mild hyperhomo-
cysteinemia is able to induce renal functional and biochemical
alterations in male adult rats that are not associated with renal
histopathologic changes.
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In the normal kidney, nitric oxide plays a key role
in the homeostatic regulation of vascular, glomerular,
and tubular function maintaining normal renal perfusion,
glomerular filtration rate (GFR), and renal vascular re-
sistance (RVR) [1, 2].
Increased superoxide anion radical (•O2−) produc-
tion inactivates the release of nitric oxide and reduces
its bioavailability by peroxynitrite (OONO−) formation.
Thus, a greater nitric oxide inactivation may reduce
medullar blood flow, contributing to the development of
renal failure [3].
Homocysteine is a thiol-containing amino acid. Ho-
mocysteine goes through the trans-sulphuration pathway
which requires vitamin B6 as a cofactor to produce cys-
tathionine, cysteine, and glutathione or is methylated to
methionine taking a methyl group from choline-derived
betaine (betaine methyl transferase) or 5-methyl-tetra-
hydrofolic acid (methionine sintetase, which needs vita-
min B12 as a cofactor) (Fig. 1) [4, 5].
Different studies have shown that hyperhomocysteine-
mia is associated with increased risk of vascular disease
involving coronary, cerebral, and peripheral arteries [6,
7]. Depending on the definition of hyperhomocysteine-
mia, 10% to 20% of the general population, more than
85% of patients with end-stage kidney disease (ESRD)
[8, 9] and up to 32% of the individuals having premature
peripheral arterial disease [10] have increased homocys-
teine levels. On the other hand, hyperhomocysteinemia
is a frequent finding in heart, liver, and renal transplant
recipients and is associated with renal dysfunction, even
though the etiologic factors have not been clearly identi-
fied [11–13].
We recently studied the impact of increased level of
homocysteine on renal function showing that hyperho-
mocysteinemia induces renal oxidative stress and renal
hemodynamic dysfunction involving altered L-arg-nitric
oxide pathway [14]. In addition, it has been found that hy-
perhomocysteinemia is also able to promote glomerular
damage [15] or generate tubulointerstitial lesions [16].
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Fig. 1. The interrelationship between ho-
mocysteine, methionine, vitamin B12, folic
acid, and choline metabolism. (Adapted from
Zeisel and Blusztajn, 1994.)
However, these morphologic findings were reported in
rats with unilateral nephrectomy or in weanling rats, two
experimental models that are exposed to other concomi-
tant vascular risk factors. Therefore, the aim of this work
is to study whether mild hyperhomocisteinemia per se
can induce renal histopathologic changes in adult Wistar
rats with normal renal function at either 10 or 44 weeks
of treatment.
METHODS
Animals
Two-month-old male Wistar rats (N =52) (180 to 220 g)
were used. The animals were maintained on a standard
rat chow (Argentine Cooperative Association, Animal
Nutritional Division) and tap water. They were housed
under a 12/12-hour day/night cycle at a steady tempera-
ture of 25◦C. After 1 week of acclimatization, they were
randomly allocated to either a normal control (N = 26) or
hyperhomocysteinemic (N = 26) group. Control and hy-
perhomocysteinemic groups had free access during 10 or
44 weeks to either tap water or homocysteine thiolactone
(HTL) (50 mg/kg/day), respectively [17].
Plasma homocysteine levels
Femoral arterial blood samples (200 lL) were with-
drawn at baseline, 10 or 44 weeks and immediately cooled
in Eppendorff tubes containing 0.1% ethylenediaminete-
traacetic acid (EDTA). Plasma was separated by centrifu-
gation at 4◦C and immediately frozen at −60◦C until the
day of analysis. Total plasma homocysteine levels were
determined using the Bio-Rad high-performance liquid
chromatography (HPLC) kit (Bio-Rad, Hercules, CA,
USA) [18].
Renal hemodynamic function determination
Hemodynamic studies were performed in conscious
unrestrained rats as previously described [19]. Briefly,
at 10 and 44 weeks, 6 animals of each group (control
and hyperhomocysteinemic) were anesthetized to can-
nulate both the femoral artery and the femoral vein.
After recovery from surgery and in euvolemic condi-
tions, a priming dose of inulin (16 mg/kg) and sodium
para-aminohippurate (PAH) (8 mg/kg) were adminis-
tered. Immediately after, a continuous intravenous in-
fusion of 0.9% NaCl containing inulin (36 mg/mL) and
PAH (11.6 mg/mL) was given at a rate of 0.0267 mL/min.
After a 105-minute equilibration period, baseline arterial
blood samples were taken.
Blood samples were used for hematocrit, inulin, and
PAH determinations. Clearances of inulin (GFR) and
PAH [renal plasma flow (RPF)] were calculated as previ-
ously described [20, 21]. RVR were calculated from mean
arterial pressure (MAP) and renal blood flow (RBF)
according to: RVR = MAP/RBF (mm Hg × min ×
100 g body weight/mL); RBF = RPF/(1-hematocrit/100)
(mL/min × 100 g body weight) [22].
Blood pressure and heart rate were monitored
throughout the study via an arterial catheter connected
to a Statham pressure transducer (Gould Instrument,
Cleveland, OH, USA) and attached to a polygraph
recorder (model 2400S) (Gould Instrument).
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Table 1. Results of the morphologic studies
Time weeks 10 10 44 44
Number 7 7 5 9
Group Control Hyperhomocysteinemia Control Hyperhomocysteinemia
Glomerular area lm2 7221 ± 321 6489 ± 302 7101 ± 299 8462 ± 325
Mesangial expansion 0 0 0 0
Glomerulosclerosis 0 0 0 0
Interstitial fibrosis 0 0 0 1/9
Anti-a-smooth muscle actin 0 0 0 0
Vessels NEMA NEMA NEMA NEMA
NEMA is not evident microscopic alterations.
Mean ± SE.
Histopathologic examination
Kidneys of 28 rats (Table 1) were fixed by perfusion
[23] with 4% paraformaldehyde in 0.135 mol/L phosphate
buffer, embedded in paraffin, and sections were stained
with hematoxylin-eosin, periodic acid-Schiff (PAS), Mas-
son’s trichrome, and Gallego (elastic fibers) following
standard methods [24] for histopathologic and morpho-
metric studies.
The presence of myofibroblasts was evaluated with im-
munomarcation against a-smooth muscle actin (a-SMA)
(Sigma Chemical Co., St. Louis, MO, USA).
Glomerular measurements (Image Pro Plus program)
were taken in each left kidney in 50 subcapsular, medium
and yuxtamedullary glomeruli, in PAS-stained sections.
Mesangial expansion and glomerular sclerosis were eval-
uated following the method of Raij et al [25], whereas in-
terstitial fibrosis was estimated according to the method
of Shih et al [26].
All these assessments were carried out under blind con-
ditions.
Chemicals and reagents
Ether (Sigma Chemical Co.) and ketamine (G &
M.S.A., Buenos Aires, Argentina) were used as anaes-
thetics. HTL were purchased from Sigma Chemical Co.
Sterile and nonpyrogenic inulin (Cypros Pharmaceutical
Co., West Carlsbad, CA, USA), and PAH ampules for in-
travenous administration (Merck & Co., Inc., West Point,
PA, USA) were used.
Statistical analysis
All values are expressed as mean ± SD. Comparisons
between hyperhomocysteinemic and control groups at 10
and 44 weeks were done by one-way analysis of variance
(ANOVA) followed by the Newman-Keuls as post hoc
test. Differences between values were considered to be
statistically significant when P < 0.05.
RESULTS
No significant differences were found in either body
weight, fluid, or food consumption between hyperhomo-
cysteinemic and control groups at 10 and 44 weeks.
Plasma homocysteine levels
Basal plasma homocysteine concentration did not dif-
fer between the two groups. After HTL administration,
total plasma homocysteine levels were 53% (10 weeks)
and 56% (44 weeks) higher in hyperhomocysteinemic
group compared to the control group (8.11 ± 1.5 and
8.27 ± 1.6 lmol/L vs. 5.3 ± 0.8 lmol/L, respectively, P <
0.001).
Renal hemodynamic function determination
Under baseline conditions, MAP and RVR were signif-
icantly higher in the hyperhomocysteinemic group than
in controls (Fig. 2A and D). Conversely, GFR (Fig. 2B)
and RPF (Fig. 2C) were significantly lower in the hyper-
homocysteinemic than in the control group.
Histopathologic evaluation
The histopathologic studies did not show any differ-
ences between the control and hyperhomocysteinemic
rats at either 10 or 44 weeks (Figs. 3 and 4).
The results of the morphometric evaluations are in-
dicated in Table 1. The glomerular area did not show
differences among the different groups.
There was only a minimal increase in the amount of
mesangial matrix in some glomeruli, but there was no
evidence of glomerulosclerosis. There was interstitial fi-
brosis in just one hyperhomocysteinemic rat.
Immunomarcation against a-SMA did not show any
difference among groups.
No renal vascular changes were observed either in the
hyperhomocysteinemic or in the control rats.
DISCUSSION
The present study examined chronic effects of mild hy-
perhomocysteinemia on renal function and morphology
in Wistar adults rats whose plasma homocysteine levels
were increased by water supplementation of homocys-
teine thiolactone (50 mg/kg/day). Despite the fact that
mild hyperhomocysteinemia induces renal functional and
biochemical alterations and increases systemic blood
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Fig. 2. Systemic and renal effects induced by hyperhomocysteine-
mia. Abbreviations are: T, hyperhomocysteinemic (gray and dark gray
columns) groups; MAP, mean arterial pressure; GFR, glomerular filtra-
tion rate; RPF, renal plasma flow; RVR, renal vascular resistance. †P
< 0.001 and ∗P < 0.05 compared with controls. Adapted and reprinted
with permission from the Annual Review of Nutrition, vol. 14, 1994,
copyright Annual Reviews, www.annualreviews.org.
pressure, they are not associated with renal morphologic
changes as evaluated by light microscopy at 10 or at
44 weeks of treatment.
Homocysteine is formed by the demethylation of me-
thionine. Increased plasma homocysteine levels can occur
as a genetic disease or as a consequence of a nutritional
deficiency in those factors that promote homocysteine
metabolism such as folic acid, vitamin B12, vitamin B6,
and betaine (Fig. 1) [4, 5, 27–29]. Another major acquired
cause of increased homocysteine values is chronic renal
failure [30].
Fig. 3. Hematoxylin-eosin–stained section of a glomerulus from hy-
perhomocysteinemic rat (magnification ×100).
Fig. 4. Hematoxylin-eosin–stained section of glomeruli and intersti-
tium from hyperhomocysteinemic rat (magnification ×200).
Homocysteine-induced oxidant injury of vascular en-
dothelium has been proposed as a more contributing
mechanism linking hyperhomocysteinemia to vascular
disease. Numerous studies have suggested that the in-
creased oxidative stress promoted by hyperhomocys-
teinemia is able to reduce nitric oxide bioavailability [31],
increase vascular tone [32], and alter elastic properties of
the vascular wall [33]. By this way, hyperhomocysteine-
mia is an important risk factor for cardiovascular disease
development.
Recent investigations suggest that oxygen radicals
may contribute to enhanced renal vascular tone, in-
creased sensitivity to vasoconstrictors and impaired re-
nal endothelium vasodilatation [34–36]. Hyperhomo-
cysteinemia promotes the reaction between increased
level of superoxide anion and nitric oxide, inducing
peroxynitrite formation which, in turn, can nitrosylate
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membrane proteins and oxidized arachidonic acid,
releasing F2-isoprostanes. These are potent renal
vasoconstrictors, leading to a fall in glomerular capil-
lary pressure and causing a marked reduction of GFR
and RBF [37–39]. This related linear increase of F2-
isoprostanes, at elevated plasma homocysteine levels [40]
might be involved on homocysteine-induced renal dele-
terious function [14, 15] and could be an important
pathogenic factor in glomerular damage associated with
hypertension [41].
Structural alterations due to hyperhomocysteinemia
have also been previously reported [16, 41]. Li et al
[41] used uninephrectomized male Sprague-Dawley rats
which, after 1 week recovery of the surgery, received
methionine (1 g/kg per day for 6 weeks, orally). At the
end of the experiment, homocysteine levels (∼=12 lmol/L
vs. 6 lmol/L) as well as proteinuria (∼=60 mg/24 hours
vs. ∼=30 mg/24 hours) were higher in these treated
rats. In addition, hyperhomocysteinemic rats showed in-
creased glomerular extracellular matrix and expanded
the glomerular mesangium with hypercellularity, capil-
lary collapse, and fibrous deposition in the glomeruli.
The glomerular injury score was higher than in control
rats (3 vs. 1). In the same paper the authors showed that
hyperhomocysteinemia is able to induce proteinuria and
glomerular sclerosis in Dahl-sensitive hypertensive rats
exposed to high salt (4% NaCl) diet [41].
Kumagai et al [16] studied the effects of folate defi-
ciency, choline deficiency, and methionine loading on ho-
mocysteinemia, renal function, and renal histopathology
on weanling male Fisher rats over a 12-week period. Fo-
late deficiency, choline deficiency, and methionine load-
ing (1.25% supplementation) synergistically induced hy-
perhomocysteinemia (up to 69.7 lmol/L) without any
change in blood pressure. A negative correlation was
found between creatinine clearance and homocysteine-
mia. The kidneys of hyperhomocysteinemic rats showed
arterial and arteriolar wall thickening and focal tubuloint-
erstitial fibrosis. The lesions of interstitial fibrosis appear
wedge-shaped at the subcapsular cortex of the kidney;
the expression of vascular endothelial growth factor was
increased in the adjacent more intact area of the cortex.
The authors suggest that the interstitial lesions could be
mediated by severe ischemia due to regional circulatory
disorder.
The more severe lesions were found in the hyperhomo-
cysteinemic rats fed a choline and folate-deficient diet. In
relation to this fact, it is interesting to point out that wean-
ling rats fed a choline-deficient diet develop acute renal
failure with lesions that vary from focal tubular necrosis
to widespread cortical necrosis or the eventual presence
of reparative changes [42]. Methionine has a protective
effect in relation to the renal lesions induced by choline
deficiency and 0.5 mg of methionine per gram of diet is
enough to prevent the renal damage [43]. So, in the ex-
periment of Kumagai et al [16] the renal lesions can not
be ascribed to choline deficiency per se because the me-
thionine concentration of the casein of the diet plus that
added to the diet (1.2%) is enough to prevent the renal
lesions.
Different hypothesis can be advanced to explain the
controversy between our results and those of Li et al
[41] and Kumagai et al [16]. It is known that even in
the same rodent species, different susceptibilities to the
same injury can be observed. By this way, the suscepti-
bility to developing glomerulosclerosis varies in different
strains of mice [44] and rats [45]. Therefore, the impact
of hyperhomocysteinemia on renal morphology might
differ related to the strain analyzed [Fisher (Kumagai),
Sprague-Dawley (Li) or Wistar (this paper)].
Another factor that could be involved in the differences
found may be the procedure employed to induce hyper-
homocysteinemia as well as the final plasma levels of
homocysteine reached. Li et al [41] induced hyperhomo-
cysteinemia by adding methionine in the drinking water,
Kumagai et al [16] added the methionine to the food; and
we have induced the hyperhomocysteinemia by adding
homocysteine thiolactone to the drinking water (50 mg/kg
per day). In all the three works homocysteinemia was in-
creased, 12, 69.7, and 8.2 lmol/L in the experiments of Li
et al [41], Kumagai et al [16] and this one, respectively,
and renal injury related to homocysteine plasma concen-
tration were observed, suggesting that no matter the pro-
cedure to induce hyperhomocysteinemia, the renal injury
extent may depend on the reached homocysteine plasma
level.
Another important consideration could be the variabil-
ity of the renal response to different types of injury de-
pending on the animal age or renal growth. Thus, while a
choline-deficient diet is able to induce acute renal failure
with tubular or cortical necrosis in weanling rats [42], the
same diet do not develops renal necrosis in adults unless
it is submitted at the compensatory renal hypertrophy
period after unilateral nephrectomy [46, 47]. In the same
line, both in rats and human beings, the glomerular mor-
phologic response to a diminished number of glomeruli
induces more deleterious consequences when the loss of
nephrons take place at an earlier period in life [48, 49].
With regard to this issue, Kumagai et al [16] highlighted
that “our preliminary experiment with older rats failed
to induce such severe renal injury, although the plasma
homocysteine level of these rats reached the same level
as that in the present study.”
CONCLUSION
Our results show that in adult rats with normal kid-
ney function, mild hyperhomocysteinemia induces renal
hemodynamic dysfunction and increased systemic blood
pressure. However, we have found no differences be-
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tween cells expressing a-SMA (myofibroblasts) in the
glomeruli or in the renal interstitium from controls or
hyperhomocysteinemic rats. The present cells have been
proved to be a good predictor of renal disease progres-
sion both in experimental animal [50] and human stud-
ies [51], supporting that no morphologic findings related
to glomerular or interstitial sclerosis or fibrosis are in-
duced by mild hyperhomocysteinemia if the animals are
not exposed to other concomitant vascular risk factors.
Taking into account that we have recently proved that
antioxidant treatment may revert homocysteine-induced
renal functional and biochemical deleterious effects, the
present results may contribute to the treatment of in-
cipient or moderate increments of homocysteine plasma
levels before the development of structural alterations,
preventing later vascular complications and reducing the
cardiovascular risk.
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